Skip to main content
German Center for Infection Research
  • Research
    • Back
    • Bridging Topics
    • Research Areas
    • Infrastructures
    • Working Groups
    • Projects
    • African Partner Institutions
    • Clinical Trials
    • Publications
  • Translation
    • Back
    • Developing Medication
    • Successful Translation
    • Collaborations
    • German Centers for Health Research
  • DZIF Academy
  • Newsroom
    • Back
    • News
    • Media Centre
    • Press Office
    • Events
    • Jobs
  • About us
    • Back
    • Portrait
    • DZIF Structure and Bodies
    • Partner Sites
    • Executive Board
    • DZIF Patient Advisory Board
    • Staff
    • Main Office
    • Donations
  • De
  • |
  • En

Search

Breadcrumb

  1. Home
  2. Search

Düsseldorf University Hospital

The University Hospital of Düsseldorf is involved in a study on the control of hepatitis C and contributes to the patient…

Sep 2022
PLoS One

Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon

Autoren
Betouke Ongwe ME et al.
Oct 2022
Nat Commun

HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design

Autoren
Dam KA et al.
Oct 2022
Mol Ther

Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection

Autoren
Krähling V et al.
Oct 2022
Trials

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Autoren
Neuhann JM et al.
Jan 2023
J Hepatol

Activation of CD4 T cells during prime immunisation determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models

Autoren
Su J et al.
Technical University of Munich

Development of a new prophylactic vaccine against Helicobacter pylori

Helicobacter pylori is one of the top 10 bacterial threats listed by the WHO, for which treatment is becoming increasingly difficult due to rising antibiotic resistance. More than half of the world's population is chronically infected with this bacterium. H. pylori is a recognised class I carcinogen ...

Hepatitis B Virus Core Capsid

Please use this image only in connection to this press release.

© Fotograf: Christian Sigl

© Fotograf: Christian Sigl
Jan 10 2023

Unraveling key determinant of successful therapeutic vaccination against chronic hepatitis B

Hepatitis B virus (HBV) infections remain a major global health problem – according to the World Health Organization (WHO) there are around 300 million HBV carriers worldwide. Current treatments

Jan 2017
Front Immunol

Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity

Autoren
Schaible UE et al.
Jul 2017
J Virol

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen

Autoren
Bauer A et al.

Pagination

Previous page ‹‹
Seite 12 Seite 13 Seite 14 Seite 15 Current page 16 Seite 17 Seite 18 Seite 19 Seite 20
Next page ››

Sitemap

  • Research
  • Translation
  • DZIF Academy
  • Newsroom
  • About us

At one click

  • Jobs
  • Media Centre
  • Press releases
  • Press contact
  • Glossary
  • Donations

Newsletter Subscription

Contact

Main Office of the DZIF e. V.
Inhoffenstraße 7
38124 Braunschweig
​

E-Mail Send mail

Fußbereichsmenü

  • DZIF Portal (internal)
  • Whistleblower system
  • Imprint
  • Privacy policy
  • Log in
  • Manage cookie consent
German Centers for Health Research
Supported by the Federal Ministry of Research, Technology and Space and the participating federal states